WeTrade Group Inc (NASDAQ: WETG) collaborated with MobiLab Medical Innovatives to launch a globally unparalleled and one-of-a-kind Monkeypox Virus testing kit with…
Emergent BioSolutions (NYSE:EBS) reported its Q2 earnings results on Monday, August 1, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Emergent BioSolutions (NYSE:EBS) reported quarterly losses of $(0.86) per share which missed the analyst consensus estimate of $0.37 by 332.43 percent. This is a 360.61 percent decrease over earnings of $0.33 per share
Emergent BioSolutions (NYSE:EBS) is set to give its latest quarterly earnings report on Monday, 2022-08-01. Here's what investors need to know before the announcement.
Analysts estimate that Emergent BioSolutions will report an earnings per share (EPS) of $0.37.
The World Health Organization (WHO) on Saturday declared the monkeypox outbreak a global emergency, its highest level of alert.
WHO Director-General Tedros Adhanom Ghebreyesus said more than 16,000 cases in more than 75 countries have now been reported around the world.